Journal article
Is ticagrelor worth its high cost and side-effects?
-
Guerbaai RA
a Departement Public Health (DPH), Faculty of Medicine , University of Basel , Basel , Switzerland.
-
Mahata I
b Tulane School of Medicine , Tulane Heart and Vascular Institute , New Orleans , LA , USA.
-
Maréchaux S
c GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Hôpital Saint Philibert, Faculty of Medicine and Maieutics, Catholic University of Lille , Lille , France.
-
Le Jemtel TH
b Tulane School of Medicine , Tulane Heart and Vascular Institute , New Orleans , LA , USA.
-
Ennezat PV
d Department of Cardiology , Centre Hospitalier Regional Universitaire Grenoble-Alpes , La Tronche , France.
Show more…
Published in:
- Acta cardiologica. - 2019
English
Ticagrelor is a reversible P2Y12 receptor antagonist that is more potent than clopidogrel. When used in combination with aspirin, it reduces cardiovascular events in patients with acute coronary syndrome. However, unbiased review of 5 randomised controlled trials indicates that although statistically significant, the clinical superiority of ticagrelor over clopidogrel is modest. Thus, identification of patients who benefit the most from ticagrelor is a priority. Besides bleeding issues, ticagrelor can frequently cause bouts of dyspnoea, which requires ticagrelor replacement by another P2Y12 receptor antagonist, with a loading dose.
-
Language
-
-
Open access status
-
closed
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/global/documents/92468
Statistics
Document views: 14
File downloads: